Levicept Ltd.

SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), is pleased to announce that it will be presenting data at forthcoming major international healthcare conferences alongside its attendance at a major global banking conference in Q4 2026. Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782 ) including new analyses will be presented at: International Association for the Study of Pain, IASP World Congress on Pain 2026 (Bangkok, 26-30 October) American College of Rheumatology, annual ACR Convergence 2026 (Orlando, 6-11 November) As previously announced, the Levicept team will also be attending the Jefferies 2026 Global Healthcare Conference (London, 16-19 November) where Levicept’s CEO Eliot Forster, CSO Simon Westbrook and CFO Darlene Deptula-Hicks will be available for meetings. Levicept is advancing a new non-opioid analgesic for OA, a condition which affects hundreds of millions of patients worldwide. Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782) were published in The Lancet i and demonstrated significant symptom control. LEVI-04 was well tolerated in this study. Previously, Levicept has presented analysis suggesting LEVI-04 may have the potential to modify the disease progression of OA. To Levicept’s knowledge, this is the first time a molecule has demonstrated analgesia and potential disease modification in a clinical study in OA. If approved, LEVI-04 would be the first new systemic treatment for OA in over two decades. Conaghan P, et al. LANCET Volume 407 , Issue 10535, 28 March–3 April 2026, Pages 1237-1248 Levicept Eliot Forster, CEO - eliot@levicept.com Media Enquiries Charles Consultants Sue Charles - Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Levicept – Levicept is a clinical stage biotechnology company developing a first-in-class non-opioid analgesic, LEVI-04, to treat the symptoms and disease of osteoarthritis. LEVI-04 is a biomimic of the neurotrophin chaperone protein p75NTR, designed to restore neurotrophin balance. LEVI-04 inhibits NT-3 while maintaining physiological activity of the remaining three neurotrophins including NGF. LEVI-04 has completed a Phase II clinical trial in more than 500 patients. It demonstrated significant symptom control and was well tolerated in this study. The data further suggest LEVI-04 may have the potential to modify the disease progression of OA. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. The company’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. Follow us on LinkedIn -

SANDWICH, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class clinical-stage treatment for osteoarthritis (OA), today announces its attendance at two major global banking conferences in H2 2026: Cantor Global Healthcare Conference 2026 (New York, 9 – 11 September)Jefferies 2026 Global Healthcare Conference (London, 16 – 19 November) CEO of Levicept Eliot Forster and CFO Darlene Deptula-Hicks are available for meetings in New York on September 9th at the Waldorf Astoria New York, 301 Park Avenue, New York NY 10022. Levicept is advancing a uniquely positioned potential non-opioid therapeutic for OA, a condition which affects millions of patients worldwide. Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782) were published in The Lanceti and demonstrated significant improvements in pain, function and patient global outcomes and a differentiated safety profile. In addition, Levicept has presented analysis suggesting LEVI-04 may be acting to modify disease in OA at major scientific conferences including ACR Convergence 2025 and EULAR 2026. The Company believes LEVI-04 is the only molecule to demonstrate the potential for disease modification alongside analgesia in a clinical study with patients with OA. Levicept Eliot Forster, CEO - eliot@levicept.com Media Enquiries Charles Consultants Sue Charles - Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Levicept – www.levicept.com Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04, p75NTR-Fc, for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. Follow us on LinkedIn - https://www.linkedin.com/company/levicept-ltd ____________________________________ i Conaghan P, et al. LANCET Volume 407, Issue 10535, 28 March–3 April 2026, Pages 1237-1248

SANDWICH, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class clinical-stage treatment for osteoarthritis (OA), today announces its attendance at two major global banking conferences in H2 2026: Cantor Global Healthcare Conference 2026 (New York, 9 – 11 September) Jefferies 2026 Global Healthcare Conference (London, 16 – 19 November) CEO of Levicept Eliot Forster and CFO Darlene Deptula-Hicks are available for meetings in New York on September 9 th at the Waldorf Astoria New York, 301 Park Avenue, New York NY 10022. Levicept is advancing a uniquely positioned potential non-opioid therapeutic for OA, a condition which affects millions of patients worldwide. Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782) were published in The Lancet i and demonstrated significant improvements in pain, function and patient global outcomes and a differentiated safety profile. In addition, Levicept has presented analysis suggesting LEVI-04 may be acting to modify disease in OA at major scientific conferences including ACR Convergence 2025 and EULAR 2026. The Company believes LEVI-04 is the only molecule to demonstrate the potential for disease modification alongside analgesia in a clinical study with patients with OA. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Levicept Eliot Forster, CEO - eliot@levicept.com Media Enquiries Charles Consultants ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Sue Charles - Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Levicept – Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04, p75NTR-Fc, for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Follow us on LinkedIn - ____________________________________ i Conaghan P, et al. LANCET Volume 407, Issue 10535, 28 March–3 April 2026, Pages 1237-1248